Compare Inovio Pharmaceuticals Inc (INO) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Wipro Limited — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Wipro Limited trades at $1.85 (market cap $18.49B). The key difference: Wipro Limited is far larger — about 207.1× Inovio Pharmaceuticals Inc's market cap, and Wipro Limited pays a 4.68% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | WIT | |
|---|---|---|
Market Cap | $89.27M | $18.49B |
Sector | Health | Technology |
52-Week High | $2.87 | $3.06 |
52-Week Low | $1.05 | $1.82 |
Enterprise Value | $60.28M | $16.42B |
Dividend Yield | — | 4.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
WIT trades at $1.855, down 0.27% with bearish technical signals. Recent quarters show earnings misses against expectations, though 2025 revenue was $890.88B with net income of $131.35B. Valuation ratios appear reasonable with P/E of 13.97 and P/B of 1.96. Analyst consensus is mixed with 19% buy ratings amid concerns about client spending and AI investments.
The outlook remains cautious due to earnings volatility and competitive pressures. Investment appeal hinges on AI partnership execution and margin stabilization, while risks include geopolitical uncertainty and tech spending constraints. Cash flow strength provides some buffer against near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
